Spruce Biosciences (SPRB) Competitors $0.07 -0.01 (-7.46%) As of 03:55 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRB vs. MEIP, SYBX, NXTC, IMNN, NERV, RLYB, RLMD, ABVC, LSB, and ATHAShould you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include MEI Pharma (MEIP), Synlogic (SYBX), NextCure (NXTC), Imunon (IMNN), Minerva Neurosciences (NERV), Rallybio (RLYB), Relmada Therapeutics (RLMD), ABVC BioPharma (ABVC), Lakeshore Biopharma (LSB), and Athira Pharma (ATHA). These companies are all part of the "pharmaceutical products" industry. Spruce Biosciences vs. MEI Pharma Synlogic NextCure Imunon Minerva Neurosciences Rallybio Relmada Therapeutics ABVC BioPharma Lakeshore Biopharma Athira Pharma Spruce Biosciences (NASDAQ:SPRB) and MEI Pharma (NASDAQ:MEIP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends, community ranking and institutional ownership. Which has preferable valuation and earnings, SPRB or MEIP? MEI Pharma has higher revenue and earnings than Spruce Biosciences. MEI Pharma is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpruce Biosciences$4.91M0.63-$47.92M-$1.28-0.06MEI Pharma$65.30M0.21$17.78M-$5.73-0.36 Does the MarketBeat Community believe in SPRB or MEIP? MEI Pharma received 381 more outperform votes than Spruce Biosciences when rated by MarketBeat users. Likewise, 63.16% of users gave MEI Pharma an outperform vote while only 54.17% of users gave Spruce Biosciences an outperform vote. CompanyUnderperformOutperformSpruce BiosciencesOutperform Votes3954.17% Underperform Votes3345.83% MEI PharmaOutperform Votes42063.16% Underperform Votes24536.84% Which has more risk and volatility, SPRB or MEIP? Spruce Biosciences has a beta of 2.39, indicating that its stock price is 139% more volatile than the S&P 500. Comparatively, MEI Pharma has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Do analysts prefer SPRB or MEIP? Spruce Biosciences presently has a consensus price target of $2.17, indicating a potential upside of 2,859.93%. Given Spruce Biosciences' higher probable upside, equities analysts plainly believe Spruce Biosciences is more favorable than MEI Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00MEI Pharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders have more ownership in SPRB or MEIP? 91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 52.4% of MEI Pharma shares are held by institutional investors. 9.1% of Spruce Biosciences shares are held by insiders. Comparatively, 3.1% of MEI Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is SPRB or MEIP more profitable? MEI Pharma has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Spruce Biosciences' return on equity of -62.10% beat MEI Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Spruce Biosciences-555.23% -62.10% -47.49% MEI Pharma N/A -84.92%-67.53% Does the media refer more to SPRB or MEIP? In the previous week, Spruce Biosciences and Spruce Biosciences both had 3 articles in the media. MEI Pharma's average media sentiment score of 0.29 beat Spruce Biosciences' score of 0.22 indicating that MEI Pharma is being referred to more favorably in the news media. Company Overall Sentiment Spruce Biosciences Neutral MEI Pharma Neutral SummarySpruce Biosciences beats MEI Pharma on 9 of the 15 factors compared between the two stocks. Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRB vs. The Competition Export to ExcelMetricSpruce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.09M$6.69B$5.47B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.087.3222.5118.54Price / Sales0.63241.49397.62103.35Price / CashN/A65.8538.1834.62Price / Book0.046.486.734.25Net Income-$47.92M$143.41M$3.22B$248.18M7 Day PerformanceN/A2.30%1.58%1.25%1 Month PerformanceN/A7.14%4.05%3.76%1 Year PerformanceN/A-2.61%15.75%5.28% Spruce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRBSpruce Biosciences2.4192 of 5 stars$0.07-7.5%$2.17+2,859.9%-88.8%$3.09M$4.91M-0.0820Analyst RevisionMEIPMEI Pharma1.6048 of 5 stars$1.99-5.2%N/A-33.1%$13.26M$65.30M-0.35100Upcoming EarningsShort Interest ↑Gap UpSYBXSynlogic2.4415 of 5 stars$1.12-3.8%N/A-36.3%$13.10M$8,000.00-0.2780Short Interest ↓Positive NewsGap DownNXTCNextCure4.6547 of 5 stars$0.46+1.0%$3.50+653.0%-61.5%$13.04MN/A-0.2290Earnings ReportShort Interest ↓News CoveragePositive NewsGap DownIMNNImunon2.7305 of 5 stars$0.86-2.0%$21.50+2,400.0%-35.9%$12.57M$500,000.00-0.4630Short Interest ↓NERVMinerva Neurosciences3.803 of 5 stars$1.76flat$5.00+184.1%-29.2%$12.31MN/A-4.009RLYBRallybio2.3249 of 5 stars$0.29-4.0%$10.00+3,332.9%-83.3%$12.12M$636,000.00-0.1840Upcoming EarningsGap UpRLMDRelmada Therapeutics4.3497 of 5 stars$0.36-44.6%$4.25+1,090.1%-91.1%$11.85MN/A-0.1210Upcoming EarningsHigh Trading VolumeABVCABVC BioPharma0.7572 of 5 stars$1.00+2.4%N/A-15.2%$11.71M$509,589.00-1.1630Earnings ReportGap DownLSBLakeshore Biopharma1.3868 of 5 stars$1.24+1.6%N/AN/A$11.54M$672.27M0.00773Short Interest ↓Positive NewsGap UpATHAAthira Pharma3.2025 of 5 stars$0.29+3.4%$13.83+4,605.2%-85.7%$11.48MN/A-0.1040Positive News Related Companies and Tools Related Companies MEI Pharma Competitors Synlogic Competitors NextCure Competitors Imunon Competitors Minerva Neurosciences Competitors Rallybio Competitors Relmada Therapeutics Competitors ABVC BioPharma Competitors Lakeshore Biopharma Competitors Athira Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRB) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SPRB Stock Free SPRB Stock Alerts